Literature DB >> 7937348

Amylin given by central and peripheral routes inhibits acid gastric secretion.

F Guidobono1, M Coluzzi, F Pagani, A Pecile, C Netti.   

Abstract

The effect of rat amylin on acid gastric secretion in the pylorus-ligated, unanesthetized rat system (Shay test) was examined. Amylin administered peripherally (2.5, 5, 10, 40, 100, or 160 micrograms/kg, SC) or intracerebroventricularly (1.5, 2.7, or 5 micrograms/rat, ICV) decreased acid gastric secretion in a dose-dependent manner. Central administration of amylin gave a stronger suppression of gastric secretion than peripheral injection. In addition, ICV-injected amylin inhibited insulin-stimulated acid gastric secretion and was effective in suppressing acid gastric secretion in rats depleted of somatostatin by pretreatment with cysteamine. This study suggests that amylin may participate in the central regulation of acid gastric secretion and indicates a possible biological function of amylin as a gastrointestinal peptide.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7937348     DOI: 10.1016/0196-9781(94)90098-1

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  4 in total

1.  Amylin given by central or peripheral routes decreases gastric emptying and intestinal transit in the rat.

Authors:  G Clementi; A Caruso; V M Cutuli; E de Bernardis; A Prato; M Amico-Roxas
Journal:  Experientia       Date:  1996-07-15

2.  Intracerebroventricular acute and chronic administration of obestatin minimally affect food intake but not weight gain in the rat.

Authors:  V Sibilia; E Bresciani; N Lattuada; D Rapetti; V Locatelli; V De Luca; F Donà; C Netti; A Torsello; F Guidobono
Journal:  J Endocrinol Invest       Date:  2006-12       Impact factor: 4.256

3.  Central ghrelin gastroprotection involves nitric oxide/prostaglandin cross-talk.

Authors:  V Sibilia; F Pagani; G Rindi; N Lattuada; D Rapetti; V De Luca; N Campanini; I Bulgarelli; V Locatelli; F Guidobono; C Netti
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

4.  Receptor activity-modifying protein-dependent impairment of calcitonin receptor splice variant Δ(1-47)hCT((a)) function.

Authors:  T Qi; M Dong; H A Watkins; D Wootten; L J Miller; D L Hay
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.